A Randomized, Double Blind, Placebo-Controlled, Dose Escalation Study of the Safety, Tolerability and Pharmacokinetics of AIN457 in Rheumatoid Arthritis Patients With Pharmacodynamics Assessed in an Expanded Cohort at the Maximum Tolerated Dose.
Phase of Trial: Phase I/II
Latest Information Update: 07 Apr 2015
At a glance
- Drugs Secukinumab (Primary)
- Indications Rheumatoid arthritis
- Focus Pharmacokinetics; Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 05 Jun 2009 Additional locations identified as reported by ClinicalTrials.gov.
- 05 Jun 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.